Approval Date: Sep 2023
Indicated for the treatment of major depressive disorder (MDD), a first-in-class drug that selectively targets the serotonin 1A receptor
Approval Date: Aug 2023
Indicated for the topical treatment of plaque psoriasis
Approval Date: Jul 2023
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Approval Date: Jul 2023
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate
Approval Date: Jul 2023
Indicated for the emergency treatment of known or suspected opioid overdose, this drug is the second over-the-counter nonprescription opioid overdose drug approved by the FDA
Approval Date: Jun 2023
For the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema
Approval Date: Jun 2023
For the treatment of hypertension and coronary artery disease
Approval Date: Jun 2023
Indicated for the treatment of spasticity resulting from multiple sclerosis, as well as in patients with spinal cord injuries or diseases.
Approval Date: May 2023
Indicated for the management of selected, refractory, patients with epilepsy, on stable regimens of anti-epileptic drugs, who require intermittent use of diazepam to control bouts of increased seizure activity
Approval Date: May 2023
Indicated for the control of absence (petit mal) seizures that are refractory to other drugs
Approval Date: May 2023
A biosimilar to Humira (adalimumab) this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s Disease, ulcerative colitis, and plaque psoriasis
Approval Date: May 2023
Indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19
Approval Date: May 2023
Indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes
Approval Date: May 2023
Indicated for the emergency treatment of known or suspected opioid overdose. This is the first approval of nalmefene hydrochloride nasal spray for health care and community use
Approval Date: May 2023
Indicated for the treatment of moderate to severe opioid use disorder (OUD). Brixadi is administered in a healthcare setting and is available in weekly or monthly formulations, each at various dosages
